SCHEMBL26422946

SCHEMBL26422946

C=C(Nc1ccc(CC)cc1C)C(C)C

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.37
GPR174 Q9BXC1 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
EGFR P00533 1/20 0.36
CYP1A2 P05177 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2C19 P33261 2/20 0.36
CYP2C9 P11712 1/20 0.36
GAA P10253 1/20 0.36
ALDH1A1 P00352 3/20 0.35
MAPT P10636 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
NR1H4 Q96RI1 1/20 0.35
TRPA1 O75762 1/20 0.35
RECQL P46063 1/20 0.34
HTT P42858 1/20 0.34
MCHR1 Q99705 1/20 0.34
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21185398 0.77 TSHR (0.34) SMN1; SMN2MEN1KMT2ACYP1A2GAA
SCHEMBL18930369 0.77 TRPA1 (0.43) SMN1; SMN2MEN1KMT2AGAAALDH1A1
SCHEMBL8767500 0.76 SMN1; SMN2 (0.41) SMN1; SMN2GPR174MEN1KMT2AEGFR
SCHEMBL7903540 0.75 ESR1 (0.52) SMN1; SMN2GPR174MEN1KMT2AEGFR
SCHEMBL8897839 0.73 RAPGEF4 (0.47) SMN1; SMN2GPR174EGFRCYP1A2GAA
SCHEMBL11512360 0.72 ALDH1A1 (0.54) SMN1; SMN2MEN1KMT2ACYP1A2CYP3A4
SCHEMBL11419588 0.72 SMN1; SMN2 (0.47) SMN1; SMN2GPR174MEN1KMT2AEGFR
SCHEMBL14415825 0.72 SMN1; SMN2 (0.57) SMN1; SMN2GPR174MEN1KMT2AEGFR
SCHEMBL9979180 0.72 NR1H4 (0.55) SMN1; SMN2GPR174MEN1KMT2AEGFR
SCHEMBL24263193 0.72 TYR (0.46) SMN1; SMN2MEN1KMT2AGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230128688-A1 DIRECTED CONJUGATION TECHNOLOGIES KLEO PHARMACEUTICALS, INC. 2023-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230128688-A1 DIRECTED CONJUGATION TECHNOLOGIES CD2BP2, CD2, CD47 SMN1; SMN2 1694/4885GPR174 2102/4885MEN1 2845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.